Open research questions in Atrial Fibrillation Management and Outcomes
342 unresolved questions extracted from the limitations and future-work sections of 995 Atrial Fibrillation Management and Outcomes papers in our library. Each links back to the study that raised it.
What the literature leaves open
The study faces challenges in translating findings from a rat model to humans. The researchers need to control for various factors that may influence the relationship between exercise intensity and atrial fibrillation. There may be technical challenges in measuring atrial fibrillation and electrophysiological parameters in rats.
Real-world inpatient bleeding data for DOACs is relatively sparse. Most evidence comes from randomized trials enrolling ambulatory patients, which may not reflect the risk profile of acutely ill inpatients. There is a need for descriptive, observational safety analyses of DOACs in real-world inpatient settings.
Real-World Bleeding Outcomes Among Hospitalized Patients Receiving Apixaban or Rivaroxaban: A Single-Center Retrospective Cohort Study · 2026 · DOIEvidence supporting specific regimens in this population remains limited and largely observational, - The proposed risk-stratified, time-dependent approach should be regarded as a pragmatic decision-support framework rather than a prescriptive treatment strategy, - Further prospective studies are needed to define the optimal antithrombotic management in this complex population
Coronary Artery Disease and Atrial Fibrillation in HighBleeding Risk: Indications and Optimal Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion · 2026 · DOIThe retrospective nature of the study, which may introduce biases. The potential for multicollinearity among predictors, which was addressed by calculating variance inflation factors (VIF). The need to handle missing data, which was addressed through multiple imputation using the 'missRanger' package.
Construction and validation of a predictive model for new-onset atrial fibrillation in patients with acute myocardial infarction following emergency percutaneous coronary intervention based on novel inflammatory markers · 2026 · DOIfurther studies are needed to validate the nomogram, - comparison of the predictive effectiveness of different inflammatory markers, - investigation of the underlying mechanisms of NOAF
Construction and validation of a predictive model for new-onset atrial fibrillation in patients with acute myocardial infarction following emergency percutaneous coronary intervention based on novel inflammatory markers · 2026 · DOIthe complex pathogenesis of AF and significant interindividual variability make it difficult to determine the specific causes in each patient, - clinical efficacy needs to be further improved, - intensive glycemic control failed to significantly reduce the risk of new-onset AF
Glucose metabolic dysregulation of diabetes and Its role in atrial fibrillation pathogenesis · 2026 · DOIinvestigating the role of HBP and O-GlcNAc modification in AF, - exploring the therapeutic potential of SGLT2 inhibitors and GLP-1 RAs for AF, - studying the effects of diabetes on cardiac metabolism and function
Glucose metabolic dysregulation of diabetes and Its role in atrial fibrillation pathogenesis · 2026 · DOIThe study faced challenges in terms of patient selection and enrollment. The study required careful consideration of biomarker confounders, such as active infection or chronic inflammatory conditions. The study had to balance the need for comprehensive biomarker analysis with the potential for procedural complications.
Biomarker response to balloon-in-basket pulsed field ablation: does posterior wall isolation matter? · 2026 · DOIThe study was a single-center study, - The sample size was limited to 60 patients, - The study did not investigate long-term outcomes
Biomarker response to balloon-in-basket pulsed field ablation: does posterior wall isolation matter? · 2026 · DOIFurther studies are needed to explore the key molecular mechanisms involved in AngII-induced AF, - Research on the effects of anti-inflammatory treatments on AF incidence
Inflammation pathways as therapeutic targets in angiotensin II induced atrial fibrillation · 2025 · DOIAlgorithm transparency and bias, - Data integration and regulatory hurdles, - Lack of explainability can hinder clinician trust and adoption, - Need for collaborative consortia and data-sharing with privacy protections
Artificial intelligence in atrial fibrillation: emerging applications, research directions and ethical considerations · 2025 · DOIDeveloping standardised, well-annotated datasets for AF, - Building large, shared databases of ECGs, patient outcomes, and imaging data, - Integrating various data modalities, - Combining multimodal data in AI models to yield new insights
Artificial intelligence in atrial fibrillation: emerging applications, research directions and ethical considerations · 2025 · DOIThe paper identifies the complexity of atrial fibrillation as a challenge, with multiple factors contributing to its initiation and perpetuation. The limited robust clinical evidence for anti-inflammatory approaches is also a challenge. The paper notes that the bidirectional relationship between atrial fibrosis and inflammation is not fully understood, presenting a challenge for the development of effective therapeutic interventions.
Further investigation is needed to develop novel therapeutic interventions to enhance clinical management of AF, - The development of gender-specific therapeutic approaches may be beneficial, - More research is needed to understand the relationship between inflammation and AF
One challenge is the complex process of atrial fibrillation, which includes multiple factors such as atrial fibrosis, fatty infiltration, inflammation, ion channel dysfunction, atrial ischemia, and vascular remodeling. Another challenge is the limited understanding of the relationship between the electroanatomical atrial substrate and function through strain analysis. A technical challenge is the use of speckle-tracking echocardiography, which requires specialized equipment and expertise.
The gap in the current literature is the poor characterization of right atrial alterations in atrial fibrillation. The gap in the current literature is the lack of understanding of the relationship between the electroanatomical atrial substrate and function through strain analysis. The gap in the current literature is the need for predictors of post-ablation AF recurrence.
Further studies are needed to explore the mechanisms of immune infiltration in AF, - The role of lactylation in other diseases should be investigated, - The diagnostic model should be validated in larger human cohorts, - The effects of lactylation on atrial metabolite and immunity should be further studied
Comprehensive analysis of lactylation-related gene and immune microenvironment in atrial fibrillation · 2025 · DOIThe mechanisms of immune infiltration in atrial fibrillation remain unclear. The association between lactylation and AF is unexplored. There is a need for therapeutic innovation in AF treatment.
Comprehensive analysis of lactylation-related gene and immune microenvironment in atrial fibrillation · 2025 · DOIThe association between IBI and NOAF in STEMI patients is unclear. There is a need to establish a precise and effective risk stratification system for NOAF in STEMI patients. The study aims to fill this gap by exploring the predictive ability of IBI for NOAF.
Predictive value of inflammatory burden index for new-onset atrial fibrillation in STEMI patients · 2025 · DOIAccurately quantifying fibrosis persists as a challenge despite advancements in imaging. The heterogeneity of fibrosis leads to distinct electrophysiological abnormalities that promote AF. Dissolving pre-existing collagen deposits within atrial tissue remains a formidable challenge.
Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets · 2024 · DOIThe precise mechanisms by which different types of fibrosis affect atrial conduction and arrhythmogenesis remain incompletely understood. Current imaging techniques lack standardization and spatial resolution sufficient to reliably quantify the extent and type of atrial fibrosis.
Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets · 2024 · DOIThe efficacy of DOACs in preventing recurrent embolic stroke of unknown source remains uncertain. The timing of initiation of anticoagulation after acute ischemic stroke is debated.
The relationship between low-intensity or moderate-intensity exercise and atrial fibrillation is not well understood. The potential mechanism linking exercise intensity to the susceptibility to atrial fibrillation is not fully explored. There is a need to investigate the effects of different intensity endurance training on atrial fibrillation in rats.
further studies with systematic adjudication, - research on the impact of antiplatelet agent use, - studies with larger sample sizes
Real-World Bleeding Outcomes Among Hospitalized Patients Receiving Apixaban or Rivaroxaban: A Single-Center Retrospective Cohort Study · 2026 · DOIWhether CR, particularly when tailored for patients with obesity, is effective to reduce AF symptom burden remains uncertain [ 6 ].
Effects on atrial fibrillation symptom burden of an obesity-focused cardiac rehabilitation program: Insights from the OPTICARE XL trial · 2026 · DOI
Most-cited papers in Atrial Fibrillation Management and Outcomes
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation · New England Journal of Medicine · 2009 · 9,241 citations
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation · New England Journal of Medicine · 2011 · 7,970 citations
- Apixaban versus Warfarin in Patients with Atrial Fibrillation · New England Journal of Medicine · 2011 · 7,568 citations
- Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins · New England Journal of Medicine · 1998 · 6,176 citations
- Prevalence of Diagnosed Atrial Fibrillation in Adults · JAMA · 2001 · 5,122 citations
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation · New England Journal of Medicine · 2013 · 4,541 citations
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials · The Lancet · 2013 · 4,423 citations
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation · New England Journal of Medicine · 2002 · 3,474 citations
- Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort · JAMA · 1994 · 2,842 citations
- Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation · Archives of Internal Medicine · 1994 · 2,625 citations
Most recent work
- Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation · New England Journal of Medicine · 2026
- Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation · New England Journal of Medicine · 2026
- Pulsed field ablation versus conventional thermal ablation for paroxysmal atrial fibrillation: 4-year outcomes in the ADVENT-LTO study · Nature Medicine · 2026
- Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation · New England Journal of Medicine · 2026
- Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial · Nature Medicine · 2026
- Inflammatory and fibrotic signaling pathways mediated by cardiac macrophages in atrial fibrillation · Frontiers in Cardiovascular Medicine · 2026
- Left atrial appendage occlusion and concomitant catheter ablation procedures · Heart Rhythm · 2026
- Weight Loss in Older Patients With Persistent Atrial Fibrillation · JAMA · 2026
- Left Atrial Appendage Closure — Should Recommendations Be Expanded? · New England Journal of Medicine · 2026
- Competing Stroke Etiologies and Outcomes After Breakthrough Ischemic Stroke on Oral Anticoagulants in Patients With Atrial Fibrillation · Neurology · 2026
Find a gap in your own Atrial Fibrillation Management and Outcomes sub-topic
This page shows what the Atrial Fibrillation Management and Outcomes literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.
Open the Research Gap Finder →